28. Buscaglia JM, Dunbar KB, Okolo PI 3rd, et al. The spiral enteroscopy training initiative: results of a

prospective study evaluating the discovery SB overtube device during small bowel enteroscopy

(with video). Endoscopy 2009;41(3):194–199.

29. Nagula S, Gaidos J, Draganov PV, et al. Retrograde spiral enteroscopy: feasibility, success, and

safety in a series of 22 patients. Gastrointest Endosc 2011; 74(3):699–702.

30. Cunningham JD, Vine AJ, Karch L, et al. The role of laparoscopy in the management of

intussusception in the Peutz–Jeghers syndrome: case report and review of the literature. Surg

Laparosc Endosc 1998;8(1):17–20.

31. Canin-Endres J, Vine AJ, Karch L, et al. Laparoscopically assisted intestinal resection in 88 patients

with Crohn’s disease. Surg Endosc 1999;13(6):595–599.

32. Johnson KN, Chapital AB, Harold KL, et al. Laparoscopic management of acute small bowel

obstruction: evaluating the need for resection. J Trauma Acute Care Surg 2012;72(1):25–30;

discussion 30–1; quiz 317.

33. Sellner F. Investigations on the significance of the adenoma-carcinoma sequence in the small bowel.

Cancer 1990;66(4):702–715.

34. Scott-Coombes DM, Williamson RC. Surgical treatment of primary duodenal carcinoma: a personal

series. Br J Surg 1994;81(10):1472–1474.

35. Chow JS, Chen CC, Ahsan H, et al. A population-based study of the incidence of malignant small

bowel tumours: SEER, 1973–1990. Int J Epidemiol 1996;25(4):722–728.

36. Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and

prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol

2008;26(18):3063–3072.

37. Hemminki K, Li X. Incidence trends and risk factors of carcinoid tumors: a nationwide

epidemiologic study from Sweden. Cancer 2001;92(8):2204–2210.

38. Thorson A, Biorck G, Bjorkman G, et al. Malignant carcinoid of the small intestine with metastases

to the liver, valvular disease of the right side of the heart (pulmonary stenosis and tricuspid

regurgitation without septal defects), peripheral vasomotor symptoms, bronchoconstriction, and an

unusual type of cyanosis; a clinical and pathologic syndrome. Am Heart J 1954;47(5):795–817.

39. Lembeck, F. [Detection of 5-hydroxytryptamine in carcinoid metastases]. Naunyn Schmiedebergs

Arch Exp Pathol Pharmakol 1954;221(1):50–66.

40. Erspamer V, Asero B. Identification of enteramine, the specific hormone of the enterochromaffin

cell system, as 5-hydroxytryptamine. Nature 1952; 169(4306):800–801.

41. Strosberg J. Neuroendocrine tumours of the small intestine. Best Pract Res Clin Gastroenterol

2012;26(6):755–773.

42. Strosberg J, Gardner N, Kvols L. Survival and prognostic factor analysis of 146 metastatic

neuroendocrine tumors of the mid-gut. Neuroendocrinology 2009;89(4):471–476.

43. Rorstad O, Klöppel G, Couvelard A, et al. Prognostic indicators for carcinoid neuroendocrine

tumors of the gastrointestinal tract. J Surg Oncol 2005; 89(3):151–160.

44. Rindi G, Klöppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro) endocrine

tumors: a consensus proposal including a grading system. Virchows Arch 2007;451(4):757–762.

45. Jann H, Roll S, Couvelard A, et al. Neuroendocrine tumors of midgut and hindgut origin: tumornode-metastasis classification determines clinical outcome. Cancer 2011;117(15):3332–3341.

46. Paulson EK, McDermott VG, Keogan MT, et al. Carcinoid metastases to the liver: role of triplephase helical CT. Radiology 1998;206(1):143–150.

47. Krenning EP, Bakker WH, Kooij PP, et al. Somatostatin receptor scintigraphy with indium-111-

DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-

octreotide. J Nucl Med 1992;33(5):652–628.

48. Oberg K, Eriksson B. Nuclear medicine in the detection, staging and treatment of gastrointestinal

carcinoid tumours. Best Pract Res Clin Endocrinol Metab 2005;19(2):265–276.

49. Walter T, Brixi-Benmansour H, Lombard-Bohas C, et al. New treatment strategies in advanced

neuroendocrine tumours. Dig Liver Dis 2012;44(2):95–105.

50. Conlon JM. Granin-derived peptides as diagnostic and prognostic markers for endocrine tumors.

Regul Pept 2010;165(1):5–11.

51. Sanduleanu S, De Bruïne A, Stridsberg M, et al. Serum chromogranin A as a screening test for

1333

gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy. Eur J Clin Invest

2001;31(9):802–811.

52. Gurusamy KS, Pamecha V, Sharma D, et al. Palliative cytoreductive surgery versus other palliative

treatments in patients with unresectable liver metastases from gastro-entero-pancreatic

neuroendocrine tumours. Cochrane Database Syst Rev 2009;(1):Cd007118.

53. Oberg K., Ferone D, Kaltsas G, et al. ENETS Consensus Guidelines for the Standards of Care in

Neuroendocrine Tumors: biotherapy. Neuroendocrinology 2009;90(2):209–213.

54. Kianmanesh R, Sauvanet A, Hentic O, et al. Two-step surgery for synchronous bilobar liver

metastases from digestive endocrine tumors: a safe approach for radical resection. Ann Surg

2008;247(4):659–665.

55. Elias D, Lefevre JH, Duvillard P, et al. Hepatic metastases from neuroendocrine tumors with a “thin

slice” pathological examination: they are many more than you think. Ann Surg 2010;251(2):307–

310.

56. Lu Y, Frobom R, Lagergren J. Incidence patterns of small bowel cancer in a population-based study

in Sweden: increase in duodenal adenocarcinoma. Cancer Epidemiol 2012;36(3):e158–e163.

57. Raghav K, Overman MJ. Small bowel adenocarcinomas–existing evidence and evolving paradigms.

Nat Rev Clin Oncol 2013;10(9):534–544.

58. Haselkorn T, Whittemore AS, Lilienfeld DE. Incidence of small bowel cancer in the United States

and worldwide: geographic, temporal, and racial differences. Cancer Causes Control

2005;16(7):781–787.

59. Goodman MT, Matsuno RK, Shvetsov YB. Racial and ethnic variation in the incidence of smallbowel cancer subtypes in the United States, 1995–2008. Dis Colon Rectum 2013;56(4):441–8.

60. Halfdanarson TR, McWilliams RR, Donohue JH, et al. A single-institution experience with 491 cases

of small bowel adenocarcinoma. Am J Surg 2010; 199(6):797–803.

61. Talamonti MS, Goetz LH, Rao S, et al. Primary cancers of the small bowel: analysis of prognostic

factors and results of surgical management. Arch Surg 2002;137(5):564–570; discussion 570–571.

62. Zaanan A, Costes L, Gauthier M, et al. Chemotherapy of advanced small-bowel adenocarcinoma: a

multicenter AGEO study. Ann Oncol 2010;21(9):1786–1793.

63. Van Weyenberg SJ, Meijerink MR, Jacobs MA, et al. MR enteroclysis in the diagnosis of smallbowel neoplasms. Radiology 2010;254(3):765–773.

64. Pilleul F, Penigaud M, Milot L, et al. Possible small-bowel neoplasms: contrast-enhanced and waterenhanced multidetector CT enteroclysis. Radiology 2006;241(3):796–801.

65. Nicholl MB, Ahuja V, Conway WC, et al. Small bowel adenocarcinoma: understaged and

undertreated? Ann Surg Oncol 2010;17(10):2728–2732.

66. Overman MJ, Hu CY, Wolff RA, et al. Prognostic value of lymph node evaluation in small bowel

adenocarcinoma: analysis of the surveillance, epidemiology, and end results database. Cancer

2010;116(23):5374–5382.

67. Barnes G Jr, Romero L, Hess KR, et al. Primary adenocarcinoma of the duodenum: management

and survival in 67 patients. Ann Surg Oncol 1994;1(1):73–78.

68. Poultsides GA, et al. Duodenal adenocarcinoma: clinicopathologic analysis and implications for

treatment. Ann Surg Oncol 2012;19(6):1928–1935.

69. Schottenfeld D, Beebe-Dimmer JL, Vigneau FD. The epidemiology and pathogenesis of neoplasia in

the small intestine. Ann Epidemiol 2009;19(1):58–69.

70. Lecuit M, Lortholary O. Immunoproliferative small intestinal disease associated with

Campylobacter jejuni. Med Mal Infect 2005;35 Suppl 2:S56–S58.

71. Nagashima R, Takeda H, Maeda K, et al. Regression of duodenal mucosa-associated lymphoid tissue

lymphoma after eradication of Helicobacter pylori. Gastroenterology 1996;111(6):1674–1678.

72. Lai EC, Lau SH, Lau WY. Current management of gastrointestinal stromal tumors–a comprehensive

review. Int J Surg 2012;10(7):334–340.

73. Kindblom LG, Remotti HE, Aldenborg F, et al. Gastrointestinal pacemaker cell tumor (GIPACT):

gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am

J Pathol 1998;152(5):1259–1269.

74. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal

stromal tumors. Science 1998;279(5350):577–580.

1334

75. Bümming P, Ahlman H, Andersson J, et al. Population-based study of the diagnosis and treatment

of gastrointestinal stromal tumours. Br J Surg 2006;93(7):836–843.

76. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence

patterns and prognostic factors for survival. Ann Surg 2000;231(1):51–58.

77. Nikfarjam M, Kimchi E, Shereef S, et al. Surgical outcomes of patients with gastrointestinal stromal

tumors in the era of targeted drug therapy. J Gastrointest Surg 2008;12(11):2023–2031.

78. Krajinovic K, Germer CT, Agaimy A, et al. Outcome after resection of one hundred gastrointestinal

stromal tumors. Dig Surg 2010;27(4):313–319.

79. Heinrich MC, Rubin BP, Longley BJ, et al. Biology and genetic aspects of gastrointestinal stromal

tumors: KIT activation and cytogenetic alterations. Hum Pathol 2002;33(5):484–495.

80. van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic

gastrointestinal stromal tumours: a phase I study. Lancet 2001;358(9291):1421–1423.